Neurol. praxi. 2020;21(1):37-40 | DOI: 10.36290/neu.2020.023

Multiple sclerosis secondary progressive form - diagnostic and treatment options

doc. MUDr. Jarmila Szilasiová, PhD.
Neurologická klinika UPJŠ LF a Univerzitná nemocnica L. Pasteura, Košice

Multiple sclerosis (MS) is a heterogeneous disease in terms of its course and prognosis. The secondary progressive form of MS is determined retrospectively, based on the presence of a disability progression, independent of relapses, after an initial relapsing course. In clinical practice, the determination of SP form is often delayed due to the lack of generally accepted diagnostic criteria and biomarkers. The work deals with a review of new definitions of this form of the disease, current and prospective treatment options.

Keywords: multiple sclerosis, secondary progressive form, definition, therapy.

Published: March 30, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Szilasiová J. Multiple sclerosis secondary progressive form - diagnostic and treatment options. Neurol. praxi. 2020;21(1):37-40. doi: 10.36290/neu.2020.023.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brochet B, Deloire MS, Perez P, Loock T, Baschet L, Debouverie M, Pittion S, Ouallet JC, Clavelou P, de Sèze J, Collongues N, Vermersch P, Zéphir H, Castelnovo G, Labauge P, Lebrun C, Cohen M, Ruet A; PROMESS study investigators. Double-blind controlled randomized trial of cyclophosphamide versus methylprednisolone in secondary progressive multiple sclerosis. PLoS One. 2017;12:e0168834. Go to original source... Go to PubMed...
    2. Buttmann M, Seuffert L, Mäder U, Toyka KV. Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study. Neurology 2016; 86: 2203-7. Go to original source... Go to PubMed...
    3. Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol. 2008; 64(3): 255-65. Go to original source...
    4. Gray O, McDonnell GV, Forbes RB. Methotrexate for multiple sclerosis. Cochrane Database Syst Rev. 2004; (2):CD003208. Go to original source...
    5. Harrison DM, Roy S, Oh J, Izbudak I, Pham D, Courtney S, Caffo B, Jones CK, van Zijl P, Calabresi PA. Association of cortical lesion burden on 7-T magnetic resonance imaging with cognition and disability in multiple sclerosis. JAMA Neurol. 2015; 72(9): 1004-12. Go to original source...
    6. Chataway J, Schuerer N, Alsanousi A, Chan D, Mac Manus D, Hunter K, Anderson V, Bangham CR, Clegg S, Nielsen C, Fox NC, Wilkie D, Nicholas JM, Calder VL, Greenwood J, Frost C, Nicholas R. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial. Lancet 2014; 383: 2213-21. Go to original source... Go to PubMed...
    7. Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Oreja-Guevara C, Boz C, Pucci E, Bergamaschi R, Lechner-Scott J, Alroughani R, Van Pesch V, Iuliano G, Fernandez-Bolaños R, Ramo C, Terzi M, Slee M, Spitaleri D, Verheul F, Cristiano E, Sánchez-Menoyo JL, Fiol M, Gray O, Cabrera-Gomez JA, Barnett M, Butzkueven H. Defining reliable disability outcomes in multiple sclerosis. Brain 2015; 138: 3287-98. Go to original source... Go to PubMed...
    8. Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová E, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open label extension. Lancet Neurol. 2018; 17(5): 405-15. Go to original source...
    9. Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, Miller DH. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 2010; 9: 681-8. Go to original source...
    10. Kappos L, Bar-Or A, Cree BA, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet 2018; 391: 1263-73. Go to original source...
    11. Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, Model F, Manfrini M, Belachew S, Hauser SL. Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the phase III OPERAI and OPERA II studies. ECTRIMS 2018. Berlin, P 547. Go to original source...
    12. Katz Sand I, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler. 2014; 20: 1654-7. Go to original source... Go to PubMed...
    13. Komori M, Lin YC, Cortese I, Blake A, Ohayon J, Cherup J, Maric D, Kosa P, Wu T, Bielekova B. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol. 2016; 3:166-79. Go to original source... Go to PubMed...
    14. La Mantia L, Milanese C, Mascoli N, D'Amico R, Weinstock-Guttman B. Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev. 2007; (1): CD002819. Go to original source...
    15. La Mantia L, Munari LM, Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev. 2010; (5): CD004678. Go to original source...
    16. Lim CK, Bilgin A, Lovejoy DB, Tan V, Bustamante S, Taylor BV, Bessede A, Brew BJ, Guillemin GJ Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression. Sci Rep. 2017; 7: 41473. Go to original source... Go to PubMed...
    17. Lorschneider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E., Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Alroughani R, Sola P, Boz C, Pucci E, Lechner-Scott J, Bergamaschi R, Oreja-Guevara C, Iuliano G, Van Pesch V, Granella F, Ramo-Tello C, Spitaleri D, Petersen T, Slee M, Verheul F, Ampapa R, Pia Amato M, McCombe P, Vucic S, Luis Sa´nchez Menoyo J, Cristiano E, Barnett MH, Hodgkinson S, Olascoaga J, Laura Saladino M, Gray O, Shaw C, Moore F, Butzkueven H, KalincikT, behalf of the MSBase Study Group. Defining secondary progressive multiple sclerosis. Brain 2016: 139; 2395-405. Go to original source...
    18. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46(4): 907-11. Go to original source...
    19. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83: 278-86. Go to original source... Go to PubMed...
    20. Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387: 1075-84. Go to original source...
    21. Lugaresi A, Caporale C, Farina D, Marzoli F, Bonanni L, Muraro PA, De Luca G, Iarlori C, Gambi D. Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis. Neurol Sci. 2001; 22: 209-10. Go to original source... Go to PubMed...
    22. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130(4): 1089-104. Go to original source... Go to PubMed...
    23. Medin Jennie. Time to, and rate of secondary progression in patients with MS. http://www.onlinelibrary.ectrims-congress.eu/ectrims/2017.
    24. Masek M, Vaneckova M, Krasensky J, Danes J, Havrdova E, Hrebikova T, Seidl Z. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status. Neuro Endocrinol Lett. 2008; 29(4): 461-6. Go to PubMed...
    25. Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: A cohort study. Lancet Neurol. 2016; 15: 574-84. Go to original source... Go to PubMed...
    26. Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004; 63(10): 1788-95. Go to original source... Go to PubMed...
    27. Pöhlau D, Przuntek H, Sailer M, Bethke F, Koehler J, König N, Heesen C, Spath P, Andersen I. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: A randomized placebo controlled multicentre study. Mult Scler. 2007; 13: 1107-17. Go to original source... Go to PubMed...
    28. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI study group. Neurology 2000; 54: 1145-55. Go to original source... Go to PubMed...
    29. Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014; 85: 67-75. Go to original source...
    30. Spelman T, Trojano M, Duquette P, Izquierdo G, Lugaresi A, Grammond P. Defining secondary progressive multiple sclerosis: is it possible to diagnose early? Mult Scler J. 2013; 19(Suppl 11): 38.
    31. Tremlett H, Zhao Y and Devonshire V. Natural history of secondary - progressive multiple sclerosis. Mult Scler. 2008; 14: 314-24. Go to original source... Go to PubMed...
    32. Vermersch P, Benrabah R, Schmidt N, Zéphir H, Clavelou P, Vongsouthi C, Dubreuil P, Moussy A, Hermine O. Masitinib treatment in patients with progressive multiple sclerosis: A randomized pilot study. BMC Neurol. 2012; 12: 36. Go to original source...
    33. von Wyl V, Benkert P, Lorscheider J, Hänni P, Lienert P, Décard B, Kuhle J, Derfuss T, Kappos L, Yaldizli Ö. Progression independent of relapse activity (PIRA) in relapsing-remitting multiple sclerosis patients on first-line immunomodulatory treatment with fingolimod vs. platform injectables. ECTRIMS, 2019; 279111; P751.
    34. Zéphir H. Progress in understanding the pathophysiology of multiple sclerosis. Rev Neurol. 2018; 174(6): 358-363. Go to original source...
    35. https://www.health.gov.sk

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.